Meet The Professors VOL 4, ISSUE 4

Faculty Affiliations

	Hyman B Muss, MD Professor of Medicine University of Vermont College of Medicine and Vermont Cancer Center Burlington, Vermont		Hope S Rugo, MD Clinical Professor of Medicine Carol Franc Buck Breast Care Center; Co-director Breast Oncology Clinical Trials Program, University of California, San Francisco Comprehensive Cancer Center San Francisco, California
	Mark D Pegram, MD Associate Professor of Medicine, David Geffen School of Medicine at UCLA; Director, Women’s Cancer Program, UCLA/ Jonsson Comprehensive Cancer Center Los Angeles, California		Sandra M Swain, MD Professor of Medicine F Edward Herbert School of Medicine, Uniformed Service University of the Health Sciences; Chief of the Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, NCI, DHHS Bethesda, Maryland

Medical Oncologist Community Panel

Alan B Astrow, MD
Brooklyn, New York

Sushil Bhardwaj, MD
Suffern, New York

Samuel N Bobrow, MD
New Haven, Connecticut

Charles M Farber, MD, PhD
Morristown, New Jersey

Leonard R Farber, MD
New Haven, Connecticut

Ellen W Friedman, MD
Bronx, New York

Carl T Henningson Jr, MD
Brick, New Jersey

Kenneth R Hoffman, MD
Teaneck, New Jersey

Stephen M Lichter, MD
Brooklyn, New York

K M Steve Lo, MD
Stamford, Connecticut

Jeffrey L Vacirca, MD
East Setauket, New York

Stanley E Waintraub, MD
Hackensack, New Jersey

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: John H Brebner, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech Inc/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Muss — Consulting Fees: Amgen Inc, Genentech Inc, Ortho Biotech Products LP, Pfizer Inc, Roche Laboratories Inc; Ownership Interest: Amgen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bristol-Myers Squibb Company, Celgene Corporation, Coley Pharmaceutical Group Inc, Genentech Inc, Genetics Institute, GlaxoSmithKline, ImClone Systems, Ligand Pharmaceuticals Incorporated, Merck and Company Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, Pfizer Inc, Sandoz, Sanofi-Aventis, Schering-Plough Corporation; Membership: American Society of Clinical Oncology. Dr Pegram — Consulting Fees: Genentech Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: Genentech Inc, Sanofi-Aventis. Dr Rugo — Contracted Research: Genentech Inc. Dr Swain — No financial interests or affiliations to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.